Pernix Therapeutics (PTX) Misses Q2 EPS by 15c

Pernix Therapeutics (NASDAQ: PTX) reported Q2 EPS of ($0.10), $0.15 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $47 million versus the consensus estimate of $50.7 million.

For earnings history and earnings-related data on Pernix Therapeutics (PTX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c